1627. Tedizolid is Well-tolerated Among Patients Receiving Prolonged Treatment Courses, Including Those Who are Intolerant of Alternative Agents

BACKGROUND: Tedizolid (TZD) is approved for acute bacterial skin and skin structure infections (ABSSSI), but often used for complicated infections to avoid linezolid (LZD) adverse events (AE), particularly when long-term treatment is indicated. This studied aimed to characterize the tolerability of...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Open Forum Infect Dis
Main Authors: Smith, Brandon, Marini, Rachel V, Spigelmyer, Amy, Clarke, Lloyd, Shields, Ryan K
Formato: Artigo
Idioma:Inglês
Publicado: Oxford University Press 2020
Assuntos:
Poster Abstracts
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7778098/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofaa439.1807
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares